MX2022009898A - Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. - Google Patents
Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.Info
- Publication number
- MX2022009898A MX2022009898A MX2022009898A MX2022009898A MX2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- dihydronaphthyridinone
- preparation
- method therefor
- medical use
- Prior art date
Links
- -1 Dihydronaphthyridinone compound Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporciona un compuesto de dihidronaftiridinona como se muestra en la fórmula (I), el compuesto que tiene un efecto inhibidor selectivo sobre RIPK1, y una sal, un estereoisómero, un solvato o un profármaco farmacéuticamente aceptable del mismo. Además, se proporciona una composición farmacéutica que contiene el compuesto y el uso del mismo en la preparación de un fármaco para tratar enfermedades o afecciones relacionadas con RIPK1. (ver Fórmula).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090252 | 2020-02-13 | ||
CN202110070075 | 2021-01-19 | ||
PCT/CN2021/076160 WO2021160109A1 (zh) | 2020-02-13 | 2021-02-09 | 二氢萘啶酮类化合物,其制法与医药上的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009898A true MX2022009898A (es) | 2022-08-25 |
Family
ID=77291388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009898A MX2022009898A (es) | 2020-02-13 | 2021-02-09 | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230139111A1 (es) |
EP (1) | EP4105216A4 (es) |
JP (1) | JP7441477B2 (es) |
KR (1) | KR20220141321A (es) |
CN (1) | CN115135648B (es) |
AU (1) | AU2021219832B9 (es) |
BR (1) | BR112022016124A2 (es) |
CA (1) | CA3167847A1 (es) |
MX (1) | MX2022009898A (es) |
TW (1) | TWI779487B (es) |
WO (1) | WO2021160109A1 (es) |
ZA (1) | ZA202209741B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011003239A (es) * | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos. |
WO2010052222A1 (en) * | 2008-11-07 | 2010-05-14 | Evotec Neurosciences Gmbh | (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists |
WO2011076734A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
WO2011076732A1 (en) * | 2009-12-21 | 2011-06-30 | Euroscreen S.A. | Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders |
RU2012112128A (ru) * | 2012-03-29 | 2013-10-10 | Холин Максим Николаевич | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ |
EA032458B1 (ru) * | 2014-01-14 | 2019-05-31 | Милленниум Фармасьютикалз, Инк. | Гетероарилы и их применение |
SI3580220T1 (sl) * | 2017-02-13 | 2022-01-31 | Bristol-Myers Squibb Company | Aminotriazolopiridini kot kinazni inhibitorji |
WO2018157277A1 (en) * | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
CN113508109B (zh) * | 2019-03-22 | 2023-02-10 | 劲方医药科技(上海)有限公司 | 取代的杂环酰胺类化合物,其制法与医药上的用途 |
-
2021
- 2021-02-09 KR KR1020227031062A patent/KR20220141321A/ko unknown
- 2021-02-09 AU AU2021219832A patent/AU2021219832B9/en active Active
- 2021-02-09 JP JP2022549239A patent/JP7441477B2/ja active Active
- 2021-02-09 TW TW110105011A patent/TWI779487B/zh active
- 2021-02-09 EP EP21754262.0A patent/EP4105216A4/en active Pending
- 2021-02-09 BR BR112022016124A patent/BR112022016124A2/pt unknown
- 2021-02-09 WO PCT/CN2021/076160 patent/WO2021160109A1/zh active Application Filing
- 2021-02-09 CN CN202180014761.0A patent/CN115135648B/zh active Active
- 2021-02-09 MX MX2022009898A patent/MX2022009898A/es unknown
- 2021-02-09 US US17/799,637 patent/US20230139111A1/en active Pending
- 2021-02-09 CA CA3167847A patent/CA3167847A1/en active Pending
-
2022
- 2022-08-31 ZA ZA2022/09741A patent/ZA202209741B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021219832A1 (en) | 2022-09-29 |
EP4105216A4 (en) | 2024-02-28 |
TWI779487B (zh) | 2022-10-01 |
JP7441477B2 (ja) | 2024-03-01 |
CN115135648B (zh) | 2024-02-09 |
WO2021160109A1 (zh) | 2021-08-19 |
BR112022016124A2 (pt) | 2022-10-25 |
AU2021219832B2 (en) | 2024-01-25 |
CN115135648A (zh) | 2022-09-30 |
JP2023513825A (ja) | 2023-04-03 |
KR20220141321A (ko) | 2022-10-19 |
AU2021219832B9 (en) | 2024-02-15 |
CA3167847A1 (en) | 2021-08-19 |
TW202140476A (zh) | 2021-11-01 |
ZA202209741B (en) | 2023-04-26 |
EP4105216A1 (en) | 2022-12-21 |
US20230139111A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
PH12018501537A1 (en) | Benzopyrazole compounds and analogues thereof | |
EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
WO2020257549A3 (en) | Compounds for treatment of pd-l1 diseases | |
MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
MX2022012056A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento. | |
JOP20220075A1 (ar) | مثبطات عامل d المكمل عن طريق الفم | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021007247A (es) | Derivados de rapamicina. | |
MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
NZ757711A (en) | Antimicrobial compounds, compositions, and uses thereof | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2022004264A (es) | Inhibidores del factor d del complemento para administracion oral. | |
PH12019500849A1 (en) | Naphthyridinone derivatives and their use inthe treatment of arrhythmia | |
MX2022013273A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso. | |
MX2021010115A (es) | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
MX2022009898A (es) | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. | |
PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators |